Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bridgepoint reiterates targets after solid first half

(Sharecast News) - Investment firm Bridgepoint said it delivered a strong first-half with "encouraging progress" on fundraising, as assets under management (AuM) jumped by a fifth compared with last year. AuM totalled $86.6bn by 30 June, up from $72.2bn a year earlier and $75.6bn at the end of the last fiscal year on 31 December. Fee-paying AuM increased by 2% year-on-year to €37.5bn.

Underlying management fee income slipped slightly to £207.1m from £211.8m a year earlier. However, when excluding catch-up fees from both periods, underlying management fee income actually increased by 11% to £201.4m.

Underlying EBITDA excluding catch-up fees increased to £122.3m from £114.6m, while performance related earnings (PRE) were more or less flat at £57.6m - representing 22% of total income.

The company reaffirmed its full-year guidance - PRE is expected to be 25% of total income in 2025 and 2026 - and said it had made solid fundraising progress for its BDL IV, BCO V and ECP VI funds during the half, with €8bn of the targeted €24bn raised.

"Bridgepoint Group delivered strong performance in the first half and we have continued to make progress towards our fundraising target of €24bn by the end of 2026," said chief executive Raoul Hughes.

"This was a result of good fund performance, product diversification and the investments we have made in our investor services team, together with strengthening LP appetite to invest in the European middle market and US electricity infrastructure."

Looking ahead, Hughes noted "signs of increasing transaction activity", with a good pipeline of exits for the next 18 months.

The stock was trading flat at 354.4p by 0956 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.